Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics announced that its CEO, John Butler, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 9:00 a.m. ET. The conference will be held in New York from June 4-6, 2024. The presentation will be accessible through a webcast on Akebia's investor website for 30 days post-event.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focusing on kidney disease, announced its participation in the 2nd Annual HCW Bioconnect Investor Conference in New York on May 20, 2024. CEO John Butler will engage in a fireside chat at 3:00 p.m. ET. The presentation will be available via webcast on Akebia's investor relations website for 30 days post-conference.
Akebia Therapeutics reported financial results for the first quarter of 2024, highlighting the FDA approval of Vafseo tablets for anemia due to chronic kidney disease. The company expects significant growth in Auryxia net product revenues in 2024 and has ample cash to support operations for the next two years.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its first-quarter financial results on May 9, 2024, and host a conference call to discuss the results and recent business highlights. The call is scheduled for 8:00 a.m. ET. Investors can access the call via phone or webcast.
Akebia Therapeutics, Inc. granted 10 newly-hired employees options to purchase 41,000 shares of common stock as inducements under Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.26 per share, with options vesting over four years. Each option has a 10-year term and is subject to company conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.